Navigation Links
Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
Date:3/2/2009

REDWOOD CITY, Calif., March 2 /PRNewswire/ -- Pearl Therapeutics, a biopharmaceutical company developing products for the treatment of widely prevalent respiratory diseases, announced today the appointment of Perry Karsen as Chief Executive Officer.

"We are delighted to attract a corporate leader with such an outstanding record of achievement," stated James W. Young, Ph.D., Venture Partner at 5AM Ventures and Executive Chairman of Pearl Therapeutics. "The Pearl team has made exceptional progress on the development of its portfolio of novel products to treat respiratory diseases and we are confident that Perry, with his extensive background and experience, will contribute significantly to the further success of the company."

"I am truly excited to join the seasoned group of professionals at Pearl working to bring new, high quality therapies to patients with serious respiratory diseases," stated Mr. Karsen. "Pearl's line of products will offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing therapeutics to achieve better clinical outcomes."

As Pearl Therapeutics' new Chief Executive Officer, Perry Karsen brings more than 25 years of experience in the biotechnology and pharmaceutical industries. Most recently, Perry served as Regional President, Asia/Pacific and Head of Worldwide Business Development at Celgene Corporation, and was also a member of the company's Management, Operating, and Product Development Committees. Previously, Perry held the position of Senior Vice President of Business Development at Human Genome Sciences, and prior to that was a General Partner at Pequot Ventures focusing on venture investments in emerging biopharmaceutical and medical device companies. Earlier, he was Vice President, Corporate Development at Bristol-Myers Squibb and Senior Vice President, Marketing at Zimmer, Inc. Perry was a Director in the Business Development department at Genentech, Inc. and Representative Director of Genentech Japan. Perry began his career with Abbott and over the course of eleven years served in roles of increasing responsibility in product development, international business management, domestic and international marketing, and licensing. He has a Masters of Management degree from Northwestern University's Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University and a B.S. in Biological Sciences from the University of Illinois, Urbana.

About Pearl Therapeutics, Inc.

Pearl is developing a portfolio of meaningfully differentiated products to treat respiratory diseases including COPD and asthma. Using its proprietary particle technology, formulation expertise, and unparalleled development experience, Pearl is rapidly advancing a pipeline of products that will offer alternatives to patients and healthcare professionals, ones that better meet their needs, and intend to improve disease management and quality of life.

Founded in 2006, Pearl Therapeutics is privately held and backed by Clarus Ventures, New Leaf Ventures and 5AM Ventures.

    Contacts:
    Pearl Therapeutics
    Adrian Smith
    650.305.2605

    For Pearl Therapeutics
    Jennifer Larson
    415.725.2017
    jlarson@labfive.com


'/>"/>
SOURCE Pearl Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pearl Therapeutics Secures $8 Million in Debt Financing
2. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
3. MUSCs Hollings Cancer Center Dedicates Edwin and Barbara Pearlstine Healing Garden Endowed with $1 Million Gift from Edwin S. Pearlstine, Jr.
4. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
5. String of fullerene pearls
6. Pearl Therapeutics Raises $15.5 Million in Private Financing
7. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
8. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
9. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
10. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
11. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... AVIV, Israel , May 24, 2016   MedyMatch ... providing physicians with artificial intelligence, real-time decision support tools in ... to present at the 2016 Israeli Advanced Technology Industries (IATI) ... of Israel,s 15th National Life Sciences ... 26th at the David Intercontinental Hotel in Tel ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for a ... image analysis. The re-branding components include a crisp, refreshed logo and a new ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... Precision Farming in 2017 and Beyond. The paper outlines the key trends that ... ag industry. , “We’ve witnessed a lot of highs and lows as the ...
(Date:5/23/2016)... 23, 2016 Oxitec CEO Hadyn ... at 10:15 a.m. ET before the United States House Committee ... mosquitos can play in controlling the spread of the ... virus.      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) ... a self-limiting gene. Trials in Brazil , ...
Breaking Biology Technology:
(Date:3/21/2016)... , March 22, 2016 ... recognition with passcodes for superior security   ... a leading provider of secure digital communications services, today ... biometric technology and offer enterprise customers, particularly those in ... facial recognition and voice authentication within a mobile app, ...
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
(Date:3/11/2016)... PUNE, India , March 11, 2016 ... to a new market research report "Image Recognition Market ... by Application (Marketing and Advertising), by Deployment Type (On-Premises ... Global Forecast To 2022", published by MarketsandMarkets, the global ... in 2015 to USD 29.98 Billion by 2020, at ...
Breaking Biology News(10 mins):